Beractant

Beractant
Names
Trade namesSurvanta, Alveofact
Clinical data
Drug classPulmonary surfactant[1]
Main usesInfant respiratory distress syndrome[1]
Side effectsLow oxygen, slow heart rate, low blood pressure, high blood pressure, apnea, blockage of the endotracheal tube[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		In the trachea[1]
Onset of actionWithin minutes[1]
Duration of action2 to 3 days[1]
Typical dose25 mg/kg[1]
External links
AHFS/Drugs.comMonograph
Legal
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only

Beractant, sold under the brand name Survanta, is a medication used to prevent and treat respiratory distress syndrome in newborns.[1] Specifically it is used in those who are born premature.[1] It is given in the trachea.[1] Effects begin within minutes and may last for up to 3 days.[1]

Common side effects include slow heart rate, low oxygen, low blood pressure, high blood pressure, apnea, and blockage of the endotracheal tube.[1] Other side effects may include sepsis.[1] It is a pulmonary surfactant derived from cows.[1]

Beractant was approved for medical use in the United States in 1991.[1] In the United States 100 mg costs about 400 USD as of 2022.[2]

Medical uses

Dosage

It is generally give at a dose of 25 mg/kg four times.[1]

Chemistry

It is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins.[3]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 "Beractant Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 10 January 2022.
  2. ↑ "Survanta Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 19 January 2021. Retrieved 10 January 2022.
  3. ↑ Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, et al. (April 2005). "A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants". Pediatrics. 115 (4): 1018–29. doi:10.1542/peds.2004-2183. PMID 15805380. S2CID 40458323.
External sites:
Identifiers:
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.